Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 9/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 11/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733312 | 0.79 | RPS6KA3 (0.34) | PTGER4RPS6KA3MMP2MMP13MMP14 | |
| SCHEMBL20733294 | 0.78 | RPS6KA3 (0.35) | RPS6KA3 | |
| SCHEMBL16775802 | 0.75 | SMN1; SMN2 (0.36) | PTGER4RPS6KA3RPS6KA2 | |
| SCHEMBL30431358 | 0.70 | ALDH1A1 (0.35) | PTGER4 | |
| SCHEMBL20733299 | 0.68 | EGLN2 (0.39) | — | |
| SCHEMBL19670139 | 0.67 | MAP4K4 (0.37) | — | |
| SCHEMBL23530203 | 0.66 | MAPK1 (0.40) | PTGER4 | |
| SCHEMBL5298418 | 0.66 | RYR2 (0.39) | PTGER4 | |
| SCHEMBL29550457 | 0.66 | MAPK1 (0.40) | PTGER4 | |
| SCHEMBL24157233 | 0.65 | KDM4E (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PTGER4 3833/4885RPS6KA3 1949/4885RPS6KA2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.